Preparat: Ceftazidim Actavis, Ceftazidim Dr. Eberth, Ceftazidim Sandoz, Ceftazidime, Fortam, Fortum, Fortum®
ATC kod: J01DD02
Substanser: ceftazidim, ceftazidimpentahydrat
Hos patienter med samhällsförvärvad pneumoni har effekten av ceftazidim visats vara likvärdig hos kvinnor och män.
Vår bedömning är att de beskrivna skillnaderna inte motiverar olika dosering eller behandling hos kvinnor och män.
The pharmacokinetics of ceftazidime was assessed in healthy volunteers (12 men, 12 women) receiving 1 g ceftazidime as bolus i.v. injection. Volume of distribution was 17% lower in women. Eight men and eight women also received 1 g ceftazidime i.m. injection. Compared to men, women had 38% higher volume of distribution, 25% lower AUC, higher Cmax and longer Tmax . Also a study in burn patients found that the volume of distribution was higher in women (20%) .In an Ethiopian study assessing appropriate dosage adjustments were made in hospitalized patients with renal impairment (40 men, 33 women), Multivariate analysis showed that there were no difference between men and women in the proportion of appropriately adjusted prescription entries per patient .
During pregnancy, renal clearance of ceftazidime has been shown to be higher, 39% during first trimester and 65 % during third trimester, than post-partum. The authors suggest that the dosage of ceftazidime should be increased in pregnancy by approximately 40% .
The clinical and bacteriological responses to ceftazidime (1 g every 8 h) versus meropenem (0.5 g every 8 h) were assessed in hospitalized patients (257 men, 152 women) with community-acquired pneumonia, according to risk factors. The responses were similar in men and women in both treatment groups .
No studies with a clinically relevant sex analysis regarding adverse effects of ceftazidime have been found.
Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).
Läkemedel innehållande ceftazidim (ATC-kod J01DD02) används huvudsakligen på sjukhus och därför saknas könsspecifika användningsdata .
Faktagranskat av: Mia von Euler
Godkänt av: Karin Schenck-Gustafsson